Welcome to our dedicated page for PTC THERAPEUTICS SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PTC THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PTC THERAPEUTICS's regulatory disclosures and financial reporting.
PTC THERAPEUTICS, INC. (PTCT) received an amended Rule 144 notice indicating that Section Six Partners, L.P., identified as an affiliate of a director, plans to sell up to 50,000 shares of common stock through Merrill Lynch on NASDAQ. The amendment revises the seller’s name and related securities information. The shares to be sold were acquired on 06/25/2013 via automatic conversion of preferred stock into common stock upon the company’s IPO, from the issuer for cash. As of 08/19/2026, there were 83,460,802 shares of common stock outstanding. Director Michael Schmertzler, a general and limited partner of Section Six Partners, disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
PTC THERAPEUTICS, INC. (PTCT) director Michael Schmertzler reported indirect sales of an aggregate 25,000 shares of common stock on August 19–20, 2026. The sales were made by Section Six Partners, L.P., where he is a general and limited partner, pursuant to a written Rule 10b5-1 plan adopted on May 14, 2026. The reported weighted average prices ranged from the low $70s to the mid $73s per share across multiple trade buckets. Schmertzler reports separate direct ownership of 163,266 shares of PTCT common stock and disclaims beneficial ownership of the partnership-held shares except to the extent of his pecuniary interest.
PTC THERAPEUTICS, INC. (PTCT) executive vice president and CLO Mark Elliott Boulding exercised stock options for 2,813 shares of common stock at an exercise price of $25.69 per share and then sold those 2,813 shares in two tranches at weighted average prices of $72.39 and $72.90 on August 17, 2026. Following the option exercise, he held 16,876 stock options under that award, which was granted on February 15, 2024 and vests over four years. These transactions were effected pursuant to a written Rule 10b5-1 plan adopted on September 10, 2025.
PTC THERAPEUTICS, INC. (PTCT) is the issuer for a planned resale of its common stock under Rule 144. Michael Schmertzler, for whose account the sale will occur, through Section Six Partners, LP, has notified of an intended sale of 50,000 common shares, expected to be executed in the open market via Merrill Lynch on NASDAQ. The shares were acquired on 07/04/2012. Shares outstanding were 83,460,802 as of 08/19/2026; this is a baseline figure, not the amount being sold.
PTC Therapeutics insider Mark Boulding filed a notice to sell 2,813 shares of common stock on or after August 17, 2026, following a stock option exercise for cash. The shares are held at Fidelity Brokerage Services and are listed on NASDAQ. The filing also lists prior sales of common stock during the past three months.
Those earlier transactions include 10,522 shares sold on June 17, 2026 and 5,079 shares sold on July 6, 2026, with the filing reporting the corresponding dollar values for each sale.
PTC Therapeutics, Inc. plans to acquire ST-920, a BLA-stage, one-time administered AAV gene therapy for Fabry disease, from Sangamo Therapeutics after being selected as winning bidder in a competitive bankruptcy auction. Terms include a $111 million upfront payment and up to $100 million in contingent milestones tied to U.S. FDA approvals.
The transaction is subject to definitive documentation, bankruptcy court approval, antitrust review and other customary closing conditions, and is expected to close in late third or early fourth quarter 2026. A rolling BLA submission for accelerated approval is expected to be completed in the fourth quarter of 2026, with a potential commercial launch in 2027 and additional regulatory filings planned outside the United States.
PTC Therapeutics, Inc. chief executive officer Matthew B. Klein reported an automatic sale of 10,292 shares of common stock on 2026-08-04 at $68.57 per share. The sale was executed under an irrevocable sell-to-cover election pursuant to a Rule 10b5-1 trading plan to satisfy tax withholding obligations upon vesting of 25,000 RSUs from an August 1, 2025 grant of 75,000 RSUs. Following this transaction, Klein directly holds 383,868 shares of common stock, which include 162 shares acquired through the employee stock purchase plan for the period ended 2026-06-30.
Matthew Klein has filed to sell common stock of PTCT under Rule 144. The filing covers 10,292 shares of common stock to be sold through Fidelity Brokerage Services LLC on or after August 4, 2026 on NASDAQ, with an aggregate market value of $705,754.35. These shares arose from restricted stock vesting granted by the issuer as compensation on August 3, 2026. The filing also reports that on May 14, 2026, Klein previously sold 12,572 shares of common stock for an aggregate market value of $917,129.43.
PTC Therapeutics, Inc. director Hege Elisabeth Sollie-Zetlmayer received multiple equity awards on July 28, 2026. Grants included 4,000 restricted stock units vesting in three equal annual installments from July 28, 2027, and 2,000 restricted stock units vesting on January 2, 2027. She was also granted stock options for 3,475 and 1,738 shares of common stock at an exercise price of $75.39 per share, vesting over 36 and six equal monthly installments respectively, with both option grants expiring on July 27, 2036.
PTC Therapeutics, Inc. director Hege Elisabeth Sollie-Zetlmayer reports beneficial ownership of 46,526 shares of common stock held directly, including multiple unvested RSU awards. She also holds several stock options over common stock, three of which are currently exercisable for 14,000, 33,250 and 17,875 shares at exercise prices of $51.96, $66.49 and $38.10, respectively, with additional option grants vesting over four years on specified schedules.